A phosphate-containing sodium citrate blood filtration replacement fluid and its preparation and application
By adding anhydrous disodium hydrogen phosphate to sodium citrate replacement solution to block calcium phosphate precipitation, a sterile, single-chamber bag containing phosphate replacement solution was prepared, solving the problems of hypophosphatemia and alkalosis in sodium citrate hemofiltration solution and achieving stability and ease of clinical application.
Patent Information
- Application Number
- CN202611232340.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-14
- Publication Date
- 2026-11-10
AI Technical Summary
Existing sodium citrate blood filtration replacement fluid lacks phosphorus, leading to complications such as hypophosphatemia and metabolic alkalosis during CRRT treatment. Furthermore, existing phosphorus-containing blood purification preparations are not suitable for sodium citrate anticoagulation scenarios, pose a risk of calcium phosphate precipitation, and have complex preparation processes, making large-scale production difficult.
Anhydrous disodium hydrogen phosphate is precisely added to sodium citrate replacement solution to block the formation of calcium phosphate precipitation by chelating with trace amounts of free calcium ions. The pH is then adjusted to the physiological range to prepare a sterile, single-chamber bag containing phosphate replacement solution, which achieves in vitro local anticoagulation, physiological phosphorus supplementation, and acid-base buffering.
It significantly reduces the risk of hypophosphatemia and metabolic alkalosis, simplifies ICU procedures, improves formulation stability, is compatible with sodium citrate anticoagulation CRRT therapy, reduces the risk of nosocomial infection, and promotes the recovery of organ function in patients.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] This invention relates to the field of blood purification preparations technology, and in particular to a phosphate-containing sodium citrate blood filtration replacement solution and its preparation and application. Background Technology
[0002] Continuous renal replacement therapy (CRRT) is a core cardiac support method in the field of critical care medicine for treating critically ill patients with acute kidney injury, sepsis, septic shock, and multiple organ dysfunction syndrome. Compared to systemic heparin anticoagulation, local extracorporeal anticoagulation with sodium citrate achieves anticoagulation by chelating free calcium ions in the extracorporeal circulation tubing. It has advantages such as low risk of systemic bleeding, no damage to platelets, and long filter life, and has now become the preferred anticoagulation regimen for CRRT in ICU critical care.
[0003] Most commercially available sodium citrate hemofiltration replacement solutions contain only sodium citrate and sodium chloride as core components, which presents several technical drawbacks for long-term clinical use: First, the prescription does not contain phosphorus. Continuous ultrafiltration in CRRT will remove a large amount of free phosphorus from the patient's blood. After 24-72 hours of continuous treatment, more than 60% of critically ill patients will develop hypophosphatemia, which can induce complications such as respiratory muscle weakness, difficulty weaning from mechanical ventilation, myocardial depression, and malignant arrhythmias, delaying renal function repair and increasing in-hospital mortality. Second, clinical phosphorus supplementation requires additional intravenous infusion of phosphate via an infusion pump. Salt increases the number of bedside tubing and the risk of cross-infection within the hospital. Furthermore, the rate of phosphorus supplementation is difficult to match the rate of phosphorus clearance through blood filtration, resulting in large fluctuations in blood phosphorus concentration and exacerbating electrolyte imbalances. Thirdly, sodium citrate is metabolized by the liver to produce a large amount of bicarbonate. Critically ill patients with impaired liver function or who are bedridden for a long time are prone to bicarbonate accumulation, which can lead to metabolic alkalosis, disrupt the body's acid-base homeostasis, and aggravate organ damage. Fourthly, the electrolyte composition lacks the physiologically essential element phosphorus, making it impossible to simulate the complete ionic environment of human blood plasma, which is not conducive to cellular energy metabolism and organ repair in critically ill patients.
[0004] To address the various clinical problems caused by phosphorus deficiency in traditional sodium citrate replacement solutions, existing technologies attempt to introduce phosphorus components into blood purification formulations. However, most publicly available phosphorus-containing blood purification preparations are based on bicarbonate dialysate systems, and their formulations are designed to be compatible with heparin anticoagulation, but not with sodium citrate anticoagulation scenarios. Some phosphorus-containing replacement solutions are prone to calcium phosphate precipitation due to the presence of calcium ions in the system, requiring strict control of the phosphorus to citrate ratio or the use of dual-compartment packaging. This results in poor formulation stability, complex preparation processes, and difficulty in achieving large-scale production and convenient clinical application. Summary of the Invention
[0005] The technical problem to be solved by this invention is to provide a phosphate-containing sodium citrate blood filtration replacement solution and its preparation and application. This solution involves precisely adding anhydrous disodium hydrogen phosphate to a standard sodium citrate replacement solution formulation. The strong chelating effect of sodium citrate on trace amounts of free calcium ions blocks the formation of calcium phosphate precipitation at the molecular level. Combined with pH adjustment to the physiological range, it simultaneously achieves the triple effects of in vitro local anticoagulation, physiological phosphorus supplementation, and acid-base buffering. The resulting formulation can be terminally sterilized on a large scale, exhibits excellent physicochemical stability, can be stored long-term in a single-chamber bag, eliminates the need for additional intravenous phosphorus supplementation in clinical practice, simplifies bedside procedures in the ICU, and significantly reduces the risk of CRRT-related hypophosphatemia and metabolic alkalosis.
[0006] The present invention solves the above-mentioned technical problems by adopting the following technical solutions: A phosphate-containing sodium citrate hemofiltration replacement solution comprises the following components: sodium citrate dihydrate 5.20~5.38 g / L, sodium chloride 5.00~5.06 g / L, anhydrous disodium hydrogen phosphate 0.15~0.20 g / L, with the balance being water for injection; the pH value of the replacement solution is 7.0~7.4.
[0007] Based on the above-mentioned feeding range of anhydrous disodium hydrogen phosphate, the total phosphate concentration corresponding to the replacement solution of the present invention is 1.0~1.5 mmol / L, which matches the physiological blood phosphorus level of the human body.
[0008] As one of the preferred embodiments of the present invention, the solution is composed of the following components: 5.29 g / L sodium citrate dihydrate, 5.03 g / L sodium chloride, 0.18 g / L anhydrous disodium hydrogen phosphate, and the balance being water for injection; the pH value of the replacement solution is 7.2, and the corresponding total phosphate concentration is approximately 1.27 mmol / L.
[0009] As one of the preferred embodiments of the present invention, the osmotic pressure of the replacement fluid is 285~295 mOsm / L.
[0010] As one of the preferred embodiments of the present invention, the replacement fluid is packaged in a single-chamber integrated multilayer co-extruded infusion bag (i.e., a single-chamber integrated non-PVC infusion bag) and prepared by terminal moist heat sterilization.
[0011] A method for preparing the above-mentioned displacement fluid includes the following steps: (1) Add some water for injection to the mixing tank and stir at room temperature; (2) Add sodium chloride, sodium citrate dihydrate, and anhydrous disodium hydrogen phosphate in sequence, and stir continuously until all solids are completely dissolved; (3) Slowly add dilute hydrochloric acid, stir evenly, and adjust the pH of the solution to 7.0~7.4; (4) Add water for injection to the total volume and mix thoroughly by circulating and stirring. (5) The medicine solution is filtered through a two-stage microporous filter cartridge; (6) The filtrate is filled into a single-chamber integrated multi-layer co-extruded infusion bag and heat-sealed. (7) After moist heat sterilization and cooling, the finished replacement solution is obtained.
[0012] As one of the preferred embodiments of the present invention, in step (1), the amount of water for injection added is 90% of the total prescription amount.
[0013] As one of the preferred embodiments of the present invention, in step (5), the two microporous filter elements are a 0.45μm pre-filter element and a 0.22μm terminal sterilization filter element, respectively.
[0014] As one of the preferred embodiments of the present invention, in step (7), the moist heat sterilization conditions are 121°C and 15 min.
[0015] The use of the above-mentioned replacement fluid in the preparation of a CRRT (Continuous Renal Replacement Therapy) drug for acute kidney injury, sepsis, septic shock, and multiple organ dysfunction syndrome.
[0016] Core design principles: Sodium citrate dihydrate can strongly chelate trace amounts of free calcium ions in the system, blocking the formation of insoluble calcium phosphate precipitates at the molecular level. This allows phosphate and citrate to be stably co-soluble in the same aqueous system for a long time, solving the industry's problem of calcium-phosphate incompatibility. It can be filled in a single-chamber bag without the need for double-chamber packaging.
[0017] Sodium citrate provides local anticoagulation during extracorporeal circulation, chelates free calcium ions in the tubing, inhibits platelet aggregation and filter coagulation, does not interfere with the patient's systemic coagulation function, and retains the core advantage of low bleeding risk of traditional prescriptions.
[0018] Anhydrous disodium hydrogen phosphate replenishes the physiological concentration of phosphorus continuously lost by CRRT, preventively corrects hypophosphatemia, and maintains myocardial and respiratory muscle contractile function and cellular ATP energy metabolism. At the same time, phosphate ions form a weak acid-base buffer pair to neutralize excess bicarbonate ions produced by sodium citrate metabolism, reducing the incidence of metabolic alkalosis.
[0019] Dilute hydrochloric acid finely adjusts the pH to 7.0~7.4, which is close to the physiological pH range of human blood plasma, reducing infusion irritation. It does not interact with phosphate or citrate and has no risk of precipitation.
[0020] The advantages of this invention compared to the prior art are: (1) Based on the core anticoagulation and osmotic pressure system of commercially available sodium citrate replacement solution, this invention adds only anhydrous disodium hydrogen phosphate as a single component, without requiring significant adjustments to the existing production line, resulting in low modification costs. Relying on the chelating effect of sodium citrate on trace calcium ions in the system, this invention avoids the risk of calcium phosphate precipitation from the source. It does not require dual-chamber packaging and can be directly filled using a single-chamber integrated multi-layer co-extruded infusion bag. It also achieves terminal moist heat sterilization at 121°C for 15 minutes. After sterilization, there are no significant changes in the appearance, pH value, and ion concentration of the solution, resulting in excellent physicochemical stability. The preparation process is simple and controllable, making it suitable for large-scale industrial production. Clinical use does not require reconstitution or mixing, and bedside operation in the ICU is convenient. It truly integrates the triple effects of in vitro local anticoagulation, physiological phosphorus supplementation, and acid-base buffering, filling the technological gap of existing products. (2) The prescription of this invention contains physiological level total phosphate, which simultaneously replenishes the phosphorus continuously lost by the body during CRRT treatment, prevents CRRT-related hypophosphatemia from the source, eliminates the need for separate intravenous phosphorus supplementation in clinical practice, reduces the number of bedside infusion devices and tubing, reduces the risk of operation error and nosocomial cross-infection, and avoids large fluctuations in blood phosphorus caused by artificial phosphorus supplementation; protects myocardial and respiratory muscle function, ensures cellular ATP energy metabolism, facilitates the recovery of organ function in critically ill patients, reduces complications such as arrhythmia and respiratory muscle weakness, and helps to shorten the hospitalization period and improve patient prognosis; (3) The phosphorus source of this invention is specially selected as anhydrous disodium hydrogen phosphate, which has a better buffering capacity than sodium dihydrogen phosphate and is more suitable for the weakly alkaline internal environment formed after sodium citrate metabolism, and the acid-base balance regulation effect is more prominent. At the same time, the total phosphate concentration is controlled within the physiological range of 1.0~1.5 mmol / L, so that while playing the role of phosphorus supplementation and buffering, it will not weaken the chelation and anticoagulation ability of sodium citrate to calcium ions. (4) The phosphate in the system of the present invention forms a physiological buffer pair, which can neutralize the excess bicarbonate produced by the metabolism of sodium citrate in the human body, significantly reducing the risk of metabolic alkalosis under long-term CRRT treatment. It is particularly beneficial for high-risk patients such as liver dysfunction, sepsis, and multiple organ failure, and better maintains the acid-base homeostasis of critically ill patients. (5) This invention fully retains the core advantages of local extracorporeal anticoagulation of sodium citrate, exerts calcium ion chelation anticoagulation effect only in the extracorporeal tubing, does not interfere with the patient's systemic coagulation state, has a low risk of bleeding, and can protect the filter's service life, making it suitable for ICU critical patients undergoing CRRT treatment with citrate anticoagulation. (6) The pH of the preparation of the present invention is controlled within the physiological range of 7.0~7.4, the osmotic pressure is stably maintained at 285~295mOsm / L, the electrolyte ratio is consistent with the physiological level of human plasma, and the infusion is less irritating; after 30 days of light irradiation (4500lx±500lx), 30 days of high temperature at 60℃, and freeze-thaw cycle, the pH fluctuation of the sample is ≤0.2, the ion concentration is stable, and it is not easy to precipitate after long-term storage after sterilization, which meets the quality requirements of medical infusion and the storage conditions are simple. Detailed Implementation
[0021] The embodiments of the present invention are described in detail below. These embodiments are implemented based on the technical solution of the present invention, and provide detailed implementation methods and specific operating procedures. However, the scope of protection of the present invention is not limited to the following embodiments. Furthermore, the raw materials, reagents, equipment, and methods used in the present invention, unless otherwise specified, are all conventional raw materials, reagents, equipment, and methods in the art, and will not be described in detail further.
[0022] Example 1 This embodiment provides a phosphate-containing sodium citrate hemofiltration replacement solution, with the following composition per 1000 mL: 5.29 g sodium citrate dihydrate, 5.03 g sodium chloride, 0.18 g anhydrous disodium hydrogen phosphate, and water for injection to 1000 mL; the pH is adjusted to 7.2 with dilute hydrochloric acid.
[0023] Specific preparation method: (1) Add 90% of the total prescription amount of water for injection to the mixing tank and stir at room temperature.
[0024] (2) Add sodium chloride, sodium citrate dihydrate and anhydrous disodium hydrogen phosphate in sequence, and stir continuously until all solids are completely dissolved.
[0025] (3) Slowly add dilute hydrochloric acid, stir evenly, and adjust the pH of the solution to 7.2.
[0026] (4) Add water for injection to the full volume and mix thoroughly by circulating and stirring.
[0027] (5) The medicine solution is filtered through two stages of microporous filter cartridges of 0.45μm and 0.22μm in sequence.
[0028] (6) The filtrate is filled into a single-chamber integrated multi-layer co-extruded infusion bag and heat-sealed.
[0029] (7) Sterilize at 121℃ for 15 minutes and cool to obtain the finished replacement solution.
[0030] The finished product in this embodiment is a colorless and clear liquid with no visible foreign matter; pH value 7.2, osmotic pressure 290 mOsm / L, and total phosphate concentration 1.27 mmol / L.
[0031] Example 2 This embodiment provides a phosphate-containing sodium citrate hemofiltration replacement solution, with the following composition per 1000 mL: 5.38 g sodium citrate dihydrate, 5.06 g sodium chloride, 0.20 g anhydrous disodium hydrogen phosphate, and water for injection to 1000 mL; the pH is adjusted to 7.4 with dilute hydrochloric acid.
[0032] Specific preparation method: (1) Add 90% of the total prescription amount of water for injection to the mixing tank and stir at room temperature.
[0033] (2) Add sodium chloride, sodium citrate dihydrate and anhydrous disodium hydrogen phosphate in sequence, and stir continuously until all solids are completely dissolved.
[0034] (3) Slowly add dilute hydrochloric acid, stir evenly, and adjust the pH of the solution to 7.4.
[0035] (4) Add water for injection to the full volume and mix thoroughly by circulating and stirring.
[0036] (5) The medicine solution is filtered through two stages of microporous filter cartridges of 0.45μm and 0.22μm in sequence.
[0037] (6) The filtrate is filled into a single-chamber integrated multi-layer co-extruded infusion bag and heat-sealed.
[0038] (7) Sterilize at 121℃ for 15 minutes and cool to obtain the finished replacement solution.
[0039] The finished product in this embodiment is a colorless and clear liquid with no visible foreign matter; the pH value is 7.4, the osmotic pressure is 295 mOsm / L, and the total phosphate concentration is approximately 1.41 mmol / L.
[0040] Example 3 This embodiment provides a phosphate-containing sodium citrate hemofiltration replacement solution, with the following composition per 1000 mL: 5.20 g sodium citrate dihydrate, 5.00 g sodium chloride, 0.15 g anhydrous disodium hydrogen phosphate, and water for injection to 1000 mL; the pH is adjusted to 7.0 with dilute hydrochloric acid.
[0041] Specific preparation method: (1) Add 90% of the total prescription amount of water for injection to the mixing tank and stir at room temperature.
[0042] (2) Add sodium chloride, sodium citrate dihydrate and anhydrous disodium hydrogen phosphate in sequence, and stir continuously until all solids are completely dissolved.
[0043] (3) Slowly add dilute hydrochloric acid, stir evenly, and adjust the pH of the solution to 7.0.
[0044] (4) Add water for injection to the full volume and mix thoroughly by circulating and stirring.
[0045] (5) The medicine solution is filtered through two stages of microporous filter cartridges of 0.45μm and 0.22μm in sequence.
[0046] (6) The filtrate is filled into a single-chamber integrated multi-layer co-extruded infusion bag and heat-sealed.
[0047] (7) Sterilize at 121℃ for 15 minutes and cool to obtain the finished replacement solution.
[0048] The finished product in this embodiment is a colorless and clear liquid with no visible foreign matter; the pH value is 7.0, the osmotic pressure is 285 mOsm / L, and the total phosphate concentration is approximately 1.06 mmol / L.
[0049] Comparative Example 1 This comparative example of a sodium citrate blood filtration replacement solution is basically the same as that in Example 1, except that anhydrous disodium hydrogen phosphate is not added. The other components, dosages, and preparation methods are completely consistent with those in Example 1.
[0050] The finished product of this comparative example is a colorless and clear liquid with no visible foreign matter; pH value 7.2, osmotic pressure 287 mOsm / L, and no phosphate components.
[0051] Comparative Example 2 This comparative example of a sodium citrate blood filtration replacement solution is basically the same as that in Example 1, except that 0.06g of calcium chloride is added. The other components, dosages and preparation methods are completely consistent with those in Example 1.
[0052] After the comparative ratio solution was prepared and left to stand for 1 hour, the solution became slightly turbid. After being sterilized by moist heat at 121°C for 15 minutes, the turbidity increased significantly, and fine white precipitates were visible, making it unsuitable for use as a qualified infusion preparation.
[0053] Performance Measurement and Comparative Analysis The finished drug solutions of this invention (Example 1) and Comparative Example 1 were subjected to light exposure (illuminance of 4500 lx ± 500 lx) for 30 days, high temperature of 60°C for 30 days, and freeze-thaw cycle tests (placed at -15°C for 2 days, then at 40°C for 2 days, repeated 3 times). The properties of the drug solutions were visually observed throughout the process, and key quality indicators such as pH value, osmotic pressure, content of active ingredients (sodium citrate, total sodium, total chlorine), and insoluble particles were measured simultaneously.
[0054] The test results are shown in Table 1.
[0055] Table 1. Detection results of the replacement fluid in this invention and Comparative Example 1
[0056] From the above results, we can conclude that: (1) After being placed at high temperature of 60°C for 30 days, under light of 4500lx±500lx for 30 days, and subjected to three freeze-thaw cycles, both of the present invention remained colorless and clear, without turbidity, precipitation or discoloration; the pH value fluctuation was ≤0.2, and the osmotic pressure, sodium citrate content, total sodium and total chlorine content, insoluble particles and other indicators showed no statistically significant changes, which fully met the quality requirements of large-volume injections; this shows that after introducing physiological concentration of total phosphate into the traditional sodium citrate replacement solution system, the present invention will not reduce the physicochemical stability of the preparation, can withstand the 121°C terminal moist heat sterilization process, and meet the quality standards for large-scale production and long-term storage.
[0057] (2) Based on the experimental results of Comparative Example 2, after the exogenous addition of calcium ions to the system, turbidity appeared in a short time. After terminal sterilization, the precipitation was further aggravated, making it impossible to prepare a qualified single-chamber bag infusion preparation. This shows that the incompatibility of calcium and phosphorus is a common technical problem in the field of blood purification preparations. However, this invention successfully broke through the technical bottleneck by designing a prescription without exogenous calcium ions and using the chelating effect of sodium citrate on trace impurity calcium ions to block the formation path of calcium phosphate precipitation at the molecular level. It does not require the use of double-chamber packaging and can be directly filled and terminal sterilized using a single-chamber integrated multi-layer co-extruded infusion bag. The preparation process is simple and controllable.
[0058] (3) Compared with Comparative Example 1, which is the existing conventional prescription, this invention retains the local anticoagulant advantages of sodium citrate and incorporates physiological level total phosphate, which can simultaneously supplement the phosphorus element continuously lost by patients during CRRT treatment. It also neutralizes the excess bicarbonate produced by citrate metabolism through phosphate buffering, thereby reducing the risk of hypophosphatemia and metabolic alkalosis from the source. At the same time, it eliminates the need for additional intravenous phosphorus supplementation in clinical practice, reduces bedside tubing and operation steps, reduces the risk of cross-infection, and significantly improves the convenience of clinical use and patient benefits.
[0059] In summary, the sodium citrate phosphate-containing blood filtration replacement solution provided by this invention successfully overcomes the calcium-phosphorus incompatibility of traditional formulations, exhibits excellent physicochemical stability, and can be mass-produced using a single-chamber bag terminal sterilization process. Simultaneously, it possesses the triple core functions of external local anticoagulation, physiological phosphorus supplementation, and acid-base buffering, effectively reducing the risk of hypophosphatemia and metabolic alkalosis associated with CRRT treatment. It is suitable for preparing CRRT continuous blood purification therapy drugs for acute kidney injury, sepsis, septic shock, and multiple organ dysfunction syndrome.
[0060] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A phosphate-containing sodium citrate blood filtration replacement solution, characterized in that, It is composed of the following components: sodium citrate dihydrate 5.20~5.38 g / L, sodium chloride 5.00~5.06 g / L, anhydrous disodium hydrogen phosphate 0.15~0.20 g / L, and the balance is water for injection; the pH value of the replacement solution is 7.0~7.
4.
2. The replacement fluid according to claim 1, characterized in that, It consists of the following components: sodium citrate dihydrate 5.29 g / L, sodium chloride 5.03 g / L, anhydrous disodium hydrogen phosphate 0.18 g / L, with the balance being water for injection; the pH of the replacement solution is 7.
2.
3. The replacement fluid according to claim 1, characterized in that, The osmotic pressure of the replacement fluid is 285~295 mOsm / L.
4. The replacement fluid according to claim 1, characterized in that, The replacement fluid is packaged in a single-chamber integrated multi-layer co-extruded infusion bag and prepared by terminal moist heat sterilization.
5. A method for preparing the displacement fluid as described in any one of claims 1 to 4, characterized in that, Includes the following steps: (1) Add some water for injection to the mixing tank and stir at room temperature; (2) Add sodium chloride, sodium citrate dihydrate, and anhydrous disodium hydrogen phosphate in sequence, and stir continuously until all solids are completely dissolved; (3) Slowly add dilute hydrochloric acid, stir evenly, and adjust the pH of the solution to 7.0~7.4; (4) Add water for injection to the total volume and mix thoroughly by circulating and stirring. (5) The medicine solution is filtered through a two-stage microporous filter cartridge; (6) The filtrate is filled into a single-chamber integrated multi-layer co-extruded infusion bag and heat-sealed. (7) After moist heat sterilization and cooling, the finished replacement solution is obtained.
6. The preparation method according to claim 5, characterized in that, In step (1), the amount of water for injection added is 90% of the total prescription amount.
7. The preparation method according to claim 5, characterized in that, In step (5), the two microporous filter elements are a 0.45μm pre-filter and a 0.22μm terminal sterilization filter, respectively.
8. The preparation method according to claim 5, characterized in that, In step (7), the moist heat sterilization conditions are 121°C and 15 min.
9. The use of the replacement fluid as described in any one of claims 1 to 4 in the preparation of a CRRT (Continuous Renal Replacement Therapy) for acute kidney injury, sepsis, septic shock, and multiple organ dysfunction syndrome.
